OncoMatch/Clinical Trials/NCT07002177
A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
Is NCT07002177 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments for metastatic breast cancer.
Treatment: FWD1802 · Palbociclib 125mg · Ribociclib 200Mg Oral Tablet · Abemaciclib 150 MG · Everolimus 10 mg — This is a Study to Evaluate the Efficacy and Safety of Multiple Combination Therapies with FWD1802 in Subjects with ER-positive/HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Disease stage
Required: Stage I, II, III, IV
Prior therapy
Must have received: endocrine therapy — adjuvant or advanced
Recurrence during or within 1 year after completing ≥2 years of adjuvant endocrine therapy; OR progression after ≥1 line of endocrine therapy for advanced breast cancer (ABC) with ≥6 months of maintenance therapy
Cannot have received: selective estrogen receptor degrader
Exception: fulvestrant
No prior SERD (selective estrogen receptor degrader) therapy except fulvestrant
Lab requirements
Blood counts
sufficient organ and bone marrow functions at screening
Kidney function
sufficient organ and bone marrow functions at screening
Liver function
sufficient organ and bone marrow functions at screening
Subject must have sufficient organ and bone marrow functions at screening.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify